HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC39A10
solute carrier family 39 member 10
Chromosome 2 · 2q32.3
NCBI Gene: 57181Ensembl: ENSG00000196950.15HGNC: HGNC:20861UniProt: Q05C42
70PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedTransporter
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
zinc ion transmembrane transportzinc ion transmembrane transporter activityapical plasma membraneplasma membraneneurodegenerative diseasetype 2 diabetes mellitusAlzheimer diseaseParkinson disease
✦AI Summary

SLC39A10 (ZIP10) is a zinc-influx transporter localized to the plasma membrane that mediates cellular zinc uptake across multiple tissues 1. Beyond basic zinc homeostasis, SLC39A10 plays critical roles in immune regulation, cellular proliferation, and development. In T cells, SLC39A10 serves as a key zinc importer upon T cell receptor activation, safeguarding DNA replication; its loss protects against autoimmune diseases including inflammatory bowel disease and experimental autoimmune encephalomyelitis 2. In oocytes and endometrial tissue, SLC39A10 is essential for early embryonic development and successful pregnancy establishment through zinc-dependent signaling pathways 34. Clinically, SLC39A10 dysregulation is associated with malignancy. In osteosarcoma, ZIP10 overexpression drives proliferation and chemoresistance via the ITGA10-mediated PI3K/AKT pathway 5. In gastric cancer, SLC39A10 upregulation correlates with poor prognosis and activates CK2-mediated MAPK/ERK and PI3K/AKT signaling 6. A novel STAT3 inhibitor suppresses gastric cancer growth through dual inhibition of MYC and SLC39A10 7. In esophageal squamous cell carcinoma, P. gingivalis infection downregulates SLC39A10 expression through a HuR-dependent circular RNA mechanism 8. These findings establish SLC39A10 as both a therapeutic target and a potential biomarker for cancer management.

Sources cited
1
SLC39A10 is a zinc transporter localized to apical membranes with demonstrated Zn2+ transport activity in renal tissues across species
PMID: 30520657
2
SLC39A10 is essential for T cell zinc homeostasis and DNA replication upon TCR activation; its loss protects against IBD and EAE
PMID: 39862347
3
SLC39A10/ZIP10 is required for zinc homeostasis in oocytes and early embryonic development beyond the 4-cell stage
PMID: 41378776
4
Uterine SLC39A10 is essential for successful pregnancy through zinc-dependent modulation of progesterone signaling in decidualizing stromal cells
PMID: 39967682
5
ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated PI3K/AKT pathway activation
PMID: 34706747
6
SLC39A10 is upregulated in gastric cancer and promotes malignancy through CK2-mediated activation of MAPK/ERK and PI3K/AKT pathways
PMID: 37524874
7
STAT3 inhibition suppresses gastric cancer growth by synergistically downregulating MYC and SLC39A10
PMID: 36804016
8
P. gingivalis infection reduces SLC39A10 mRNA stability in esophageal squamous cell carcinoma through HuR-mediated mechanisms
PMID: 40701334
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.50Moderate
type 2 diabetes mellitusOpen Targets
0.42Moderate
Alzheimer diseaseOpen Targets
0.37Weak
Parkinson diseaseOpen Targets
0.37Weak
lysosomal storage diseaseOpen Targets
0.37Weak
multiple sclerosisOpen Targets
0.37Weak
upper extremity fractureOpen Targets
0.29Weak
crush injuryOpen Targets
0.28Weak
smoking initiationOpen Targets
0.22Weak
preeclampsiaOpen Targets
0.21Weak
depressive disorderOpen Targets
0.20Weak
liver diseaseOpen Targets
0.19Weak
placental retentionOpen Targets
0.19Weak
MyoclonusOpen Targets
0.17Weak
ovarian dysfunctionOpen Targets
0.17Weak
placenta praeviaOpen Targets
0.16Weak
neoplasmOpen Targets
0.10Suggestive
gastric cancerOpen Targets
0.09Suggestive
mental or behavioural disorderOpen Targets
0.08Suggestive
hepatocellular carcinomaOpen Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
SLC30A5Protein interaction87%SLC30A7Protein interaction85%SLC30A4Protein interaction76%SLC30A9Protein interaction76%SLC39A9Protein interaction76%SLC30A6Protein interaction76%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
37%
Ovary
29%
Heart
25%
Lung
20%
Liver
7%
Gene Interaction Network
Click a node to explore
SLC39A10SLC30A5SLC30A7SLC30A4SLC30A9SLC39A9SLC30A6
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q05C42
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.33Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.20 [0.12–0.33]
RankingsWhere SLC39A10 stands among ~20K protein-coding genes
  • #6,763of 20,598
    Most Researched70
  • #1,363of 17,882
    Most Constrained (LOEUF)0.33 · top 10%
Genes detectedSLC39A10
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Cloning, function, and localization of human, canine, and Drosophila ZIP10 (SLC39A10), a Zn
PMID: 30520657
Am J Physiol Renal Physiol · 2019
1.00
2
SLC39A10 is a key zinc transporter in T cells and its loss mitigates autoimmune disease.
PMID: 39862347
Sci China Life Sci · 2025
0.90
3
Porphyromonas gingivalis-induced HuR upregulation suppresses SLC39A10-derived hsa_circ_0057552 in esophageal squamous cell carcinoma.
PMID: 40701334
Microbes Infect · 2025
0.80
4
ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway.
PMID: 34706747
J Exp Clin Cancer Res · 2021
0.70
5
Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer.
PMID: 36804016
Pharmacol Res · 2023
0.60